CClinicalTrials.gg
Status unknownNCT04640363Updated Jan 15, 2021

Combi-elastography Assessment of HCC Recurrence After Thermal Ablation Multi-center Study

An observational study in HCC and Recurrence Tumor, sponsored by Chinese PLA General Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by Chinese PLA General Hospital · Observational

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Combined F index, A index,ATT index and spleen stiffness to predict tumor recurrence in different liver settings after thermal ablation of HCC.

Read the detailed description

Thermal ablation is one of the established method for HCC treatment. Postoperative recurrence of HCC is one of the major factors leading to poor prognosis of HCC patients. Most studies have shown that the risk factors of recurrence include tumor size, tumor number and intrahepatic spread, etc.

Besides, the carcinogenic effects of inflammatory activity and fibrosis in liver background caused by chronic hepatitis also be related to the recurrence. In the study, combi-elastography imaging technology , not only the F index which is related to liver fibrosis stage can be obtained, but also the A index which is related to inflammation activity can be measured, this may provide a more valuable method for tumor recurrence of early prediction.

02

Conditions studied

  • HCC
  • Recurrence Tumor

Browse trials for

Keywords

  • Thermal ablation
  • Elastography
  • Ultrasound
  • Recurrence
  • Predictive Cancer Model
03

In context

Recurrence

4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.

This study's planned enrollment of 300 is above the median of 200 across 702 observational studies indexed under Recurrence.

Browse Recurrence studies →

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients who underwent thermal ablation of HCC will be observed and evaluate the predictive power of combined elastography for tumor recurrence.

Inclusion criteria

  • Aged 18 to 80 years of age, and gender not limited;Chronic hepatitis B patients;The lesions of liver have the histopathological diagnosis of HCC and within MiLan criteria;All lesions were performed thermal ablation surgery;Sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  • Lesions that unrealized complete inactivation evaluation by the enhanced imaging;Merging other systems' serious illness that can't cooperate with elastic imaging checking(such as heart failure, renal failure, such as mental illness);After liver transplantation patients;Patients with pregnancy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. F index

    F index is linked to the degree of liver fibrosis,and it can be available by ultrasound elastography checking.

    Time frame: baseline

  2. A index

    A index is linked to the degree of hepatitis,and it can be available by ultrasound elastography checking.

    Time frame: baseline

  3. ATT index

    ATT index is linked to the degree of steatosis of liver,and it can be available by ultrasound elastography checking.

    Time frame: baseline

  4. Spleen stiffness

    Spleen stiffness can be available by ultrasound elastography checking.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
    • Ping Liang, Doctor · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04640363
Lead sponsor
Chinese PLA General Hospital
Responsible party
Ping Liang (Chief physician, Chinese PLA General Hospital) — Principal investigator
First posted
Nov 23, 2020
Start date
Dec 1, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Jan 15, 2021

Study contacts

Jie Yu, Doctor
Contact
yu-jie301@hotmail.com
010-66937981
Ping Liang, Doctor
principal investigator · Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion